PO-0687: Technical feasibility of whole breast radiotherapy for local relapse after a previous partial breast irradiation  by Leonardi, M.C. et al.
S260  2nd ESTRO Forum 2013 
2Mount Vernon Cancer Centre, Radiotherapy, Northwood, United 
Kingdom  
3Guys and St. Thomas, Radiotherapy, London, United Kingdom  
 
Purpose/Objective: Radiotherapy quality assurance (RTQA) is now a 
requirement of radiotherapy clinical trials since poor protocol 
compliance has been shown to impact on outcomes. We aim to 
determine the degree of variation in lung cancer target volume 
delineation using pre-accrual benchmark cases. 
Materials and Methods: The IDEAL-CRT trial which is investigating 
isotoxic dose escalation and acceleration in lung cancer chemo-
radiotherapy requires all prospective principal investigators to submit 
pre-accrual contouring benchmark cases. The cases are assessed for 
protocol compliance and if necessary clinicians are asked to resubmit 
their contours following amendment. We collected all of the 
benchmark cases that had been submitted by June 2012 by 
prospective trial centre principal investigators in DICOM format. Each 
exercise was analysed using a tumour management group (TMG) 
consensus contour and Dice coefficient (DC), Jaccard index (JI) and 
geographical miss index (GMI) was calculated for each individual 
structure. The data was pre-processed to ensure uniform structure 
nomenclature and then analysed using automated trial analysis tools 
built using MATLAB R2011a and CERR v.4.0. 
Results: Up until May 2012 11 clinicians had submitted a total of 21 
benchmark cases; 11 for contouring case 1 and 10 for contouring case 
2. In total approximately 160 individual structure contours were 
analysed. Structures analysed included GTV, CTV, PTV, spinal cord 
(SC), right lung (RL), left lung (LL), heart and oesophagus. All 
conformity indices showed varying levels of conformity in clinician 
contouring. For IDEAL-CRT case 1 the median JI for the SC was 0.40 
(Interquartile Range (IQR) 0.04), the heart 0.90 (IQR 0.05), the GTV 
0.65 (IQR 0.16) and the oesophagus 0.41 (IQR0.08). For IDEAL-CRT 
case 2 the median JI for the SC was 0.46 (IQR 0.06), the heart 0.87 
(IQR 0.04), the GTV 0.77 (IQR 0.07) and the oesophagus 0.48 (IQR 
0.07). 
Conclusions: Our results show that clinician target volume conformity 
varies significantly within the IDEAL-CRT trial. Our results also suggest 
that the degree of variation depends upon the target structures shape 
and complexity. Prospective individual case review for the first 1-3 
cases is standard for this trial.  
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Purpose/Objective: To determine role of single photon emission 
tomography (SPECT) with 99mTc-MIBI and computerized tomography 
(CT) in selection of patients with non small cell lung cancer (NSCLC) 
for radiation therapy. 
Materials and Methods: SPECT with 99mTc-MIBI was performed after 
conventional staging in 84 NSCLC patients. Acquisition was started 15 
min after i/v injection of 740 MBq of 99mTc-MIBI. SPECT images of the 
chest were acquired over 360° using the following parameters: a 64 -
64 word matrix, a 3° angular step, and 30 s/frame. Diagnostic results 
of SPECT and conventional CT staging were validated by histological 
examinations of operation material. Various diagnostic strategies were 
tested as a tools for noninvasive staging of NSCLC and subsequent 
guidance of radiotherapy strategy. 
Results: According to histological verification 35 of 84 evaluated 
patients had lymh node (LN) invasion by NSCLC. Sensitivity (Sen), 
specificity (Sp) and accuracy (Ac) of SPECT in diagnosis of LN invasion 
by NSCLC were as follows: 80%, 67%, 72%. Diagnostic accuracy of CT 
for detection of LN involvement was inferior to SPECT: Sen – 70%, Sp - 
63%, Ac - 66%.  
Only combination of SPECT and CT data offer important diagnostic 
solutions. If LN involvement was detected by at least one of these 
methods Sen reached 94% with corresponded Sp -52%, Ac – 70%. This 
strategy was 88% sensitive for diagnosis of N2 LN invasion. It means 
that patients with normal SPECT and CT are suitable for curative 
radiosurgery without additional invasive staging procedures. 
In patients without pneumonia or atelectasis and SPECT plus CT sings 
of LN invasion Sp reached 97%, N2 invasion was also detected with 
high Sp (88%). Patients from this group are candidates for palliative 
radiotherapy. 
Conclusions: 
1. NSCLC patients without signs of LN involvement on SPECT and CT 
are suitable for curative radiosurgery.  
2. Patients without pneumonia or atelectasis and signs of N2 LN 
invasion detected on SPECT and CT are candidates for palliative 
irradiation. 
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Purpose/Objective: Tumor tissue can be re-oxygenated by 
inactivating peroxidase/catalase in the tumor tissue through the 
application of H2O2. This H2O2 is then degraded to produce oxygen. In 
this way, low-LET radioresistant tumors can be transformed into 
radiosensitive ones. Recently, we have developed a new enzyme-
targeting bio-radiosensitization treatment utilizing H2O2 for 
intratumoral injection (KORTUC II), and confirmed the safety & 
effectiveness of the treatment mainly for patients with locally 
advanced neoplasms (Ogawa Y et al. Int J Oncol 34: 609-618, 2009, 
39: 553-560, 2011). Therefore, in the study, we applied KORTUC II for 
non-surgical treatment for patients with breast cancer of stages I or II 
(KORTUC-BCT). The purpose of the present study was to establish a 
non-surgical BCT utilizing KORTUC II radiosensitization treatment.  
Materials and Methods: A new bio-radiosensitizing agent containing 
0.5% H2O2 and 0.83% sodium hyaluronate (a CD44 ligand) has been 
developed for intra-tumoral injection. This new method, named 
KORTUC II, was approved by our local ethics committee for the 
treatment of breast cancer and metastatic lymph nodes. A total of 
early-stage breast cancer pts. (stage I, 17 pts; stage II, 31 pts) were 
enrolled in the KORTUC II trial after providing fully informed consent. 
Mean age of the pts. was 60.8 years. The agent was injected into 
breast tumor tissue twice a week under US guidance, just prior to 
each administration of radiotherapy (RT). Hypofraction RT was 
administered for the breast & axilla using a tangential fields approach 
and field-in-field method; the energy level was 4 MV and the total RT 
dose was 44 Gy administered as 2.75 Gy/fraction. An electron boost of 
3 Gy was added three times. 
Results: Treatment was well tolerated with minimal adverse effects in 
all 48 pts. A total of 44 pts achieved cCR according to PET-CT and 
dynamic MRI study, and the study has not been performed for the 
remaining 4 patients yet. No patients showed any significant 
complications (excluding mild dermatitis: Grade I, 29 pts; Grade II, 19 
pts), and cosmetic results were excellent/good for 41 pts (85.4%). 
Eighteen pts. under 75 years old with stage II breast cancer underwent 
induction chemotherapy prior to KORTUC II treatment, and 41 pts. 
with ER-positive tumors also received hormonal therapy following 
KORTUC II. The mean duration of follow-up as of the end of June 2012 
was 33.6 months, at which time all 48 pts. were alive without any 
distant metastases. Only 1 pt. had local recurrence, which was 
discovered after 34 months of follow-up. The local control rate was 
97.9%. 
Conclusions: Non-surgical KORTUC-BCT can be performed using 
KORTUC II, which has three major characteristics: image-guidance by 
US; enzyme-targeting of peroxidase/catalase; and targeting of breast 
cancer stem cells via the CD44 receptor. KORTUC-BCT offers great 
potential as a viable non-invasive replacement for surgical BCT. 
Because KORTUC II is effective & safe, it has great potential to 
become a viable non-invasive replacement for surgical procedures and 
a valuable bio-radiosensitization method for low LET (linear energy 
tranfer)-radioresistant neoplasms. 
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Purpose/Objective: The present study is specifically addressed to 
investigate the feasibility of salvage radiotherapy treatment involving 
the whole breast in patients with local relapse managed with a second 
2nd ESTRO Forum 2013   S261 
conservative surgery after partial breast irradiation (PBI) for primary 
tumor 
Materials and Methods: Patients with local recurrence in quadrants 
other than the previous one treated with full dose intraoperative 
electrons (ELIOT), who received a second breast conservative surgery, 
are enrolled in this ongoing phase I/II study called POLO ( Partially 
Omitted LObe). The primary endpoint is acute toxicity. The area 
previously irradiated with PBI is identified through surgical clips, 
inserted at the time of first quadrantectomy. The treatment volume 
comprise the whole breast minus the part previously irradiated with 
PBI. The whole breast and the recurrent tumor bed are planned to 
receive a dose of 45 Gy and 50 Gy , respectively, in 20 fractions, 
5d/wk within 4 weeks. According to the protocol, 5%, 25% 50% and 
95% of the area ELIOT should not receive more than 20Gy, 15 Gy, 10 
Gy and 5 Gy, respectively. Treatment plans are generated using 
helical tomotherapy (Tomotherapy Inc., Madison, WI) 
Results:  
  
So far, 3 patients entered the study. The mean age was 59 years. The 
histology at time of recurrence was invasive and the mean tumor size 
was 0.6 mm. All patients had quadrantectomy with negative margins 
and sentinel node biopsy. The mean time between initial radiotherapy 
and reirradiation was 100 months. All patients had been given PBI with 
21 Gy -full dose intraoperative electrons. The salvage radiotherapy 
comprises whole breast irradiation minus PBI area: by exploiting 
helical tomotherapy , a well-demarcated cold area of underdosage in 
the previously irradiated ELIOT area is created (Fig.1). The following 
treatment plan parameters are given as mean values. The 5%, 25%, 
50% and 95% of the volume of the previously ELIOT area were given 
21.6 Gy, 13.8 Gy, 8.8 Gy, 3.6 Gy respectively. Regarding the whole 
breast, V95% and V90% were 88.1% and 95.4%, respectively , Dmax was 
113.5 % ( with V 107% being 1,25 %) and Dmean were 99.5%. Proper 
DVH constraints and penalities are applied to improve target coverage 
while minimizing the previously irradiated area. Acute toxicity was 
excellent. During treatment the maximum RTOG grade was G2 
erithema (1 patient) and G2 patchy desquamation ( 1 patient) , not 
involving the ELIOT region. One month after, no side effects were 
recorded. 
Conclusions: Given the increased numbers of patients treated with 
conservative surgery and partial breast irradiation, the management 
of tumor reappearances in the untreated remaining breast is bound to 
be a matter of controversy. The technical feasibility of retreatment of 
the whole breast while sparing the primary tumor bed region 
previously irradiated with a PBI modality is a step to investigate.  
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Purpose/Objective: The advantage of Intensity Modulated 
Radiotherapy over tridimensional conformal radiotherapy (3D-CRT) for 
breast cancer remains controversial. However, target volume 
coverage and healthy tissue protection are not adequate with 3D-CRT 
under certain complex anatomical conditions. We present here the 
dosimetric results of the first patients treated with volumetric 
modulated arctherapy (VMAT) at our institution. 
Materials and Methods: Nine patients whose PTV coverage was 
unsatisfactory with 3D-CRT were selected. They were all replanned 
and treated with VMAT. A 7 mm extension was used to create the 
PTVs from the breast and lymph nodes CTVs, excluding the first 5 mm 
under the skin. Radiation was delivered by using two 6 MV photons 
partial arcs of 240°. The prescribed doses were 52.2 Gy to the breast 
and lymph nodes and 63.2 Gy to the tumor bed in 29 fractions, using 
the integrated boost method. Dosimetric results regarding PTV 
coverage and normal tissues protection (including contralateral 
breast, ipsilateral and contralateral lungs and heart) were collected. 
Results: On average, 90% and 95% of the breast PTV received 
respectively 97.2 % [93.2 -99, 9] and 91.7 % [80.6 - 98.2] of the 
prescribed dose. Ninety % and 95 % of the supraclavicular PTV 
received respectively 94.6 % [84 - 100] and 88.5 % [72-98] of the 
prescribed dose. For internal mammary chain volume, 90 % and 95 % 
of the PTV received respectively 96.4 % [87 - 100] and 90 % [75 - 100] 
of the prescribed dose. For ipsilateral lung, the volume receiving 5 Gy 
(V5) was 90 % [75-100], the volume receiving 20 Gy (V20) was 23.6% 
[13.7 - 35] and the volume receiving 30 Gy (V30) was 9.7% [4.7 - 14]. 
The average ipsilateral lung dose was 15 Gy [11-19]. For the 
contralateral lung, V5 was 38.9 % [16.6 to 68.5], V10 was 5.4 % [0-15] 
and the average dose was 5 Gy [3.4 to 7.2]. For the heart, V5 was 78.1 
% [49 - 100] and V35 was 0.8 % [0 -5]. The average heart dose was 14 
Gy [9-19]. For contralateral breast, V5 was 23.6 % [0.8 to 64.9] and 
V10 was 4.4 % [0 -20]. The average dose was 4.1 Gy [2.1 -7.3]. The 
average number of monitor unit was 568 [448-772]. 
Conclusions: RapidArc treatment yielded satisfactory PTV coverage 
while ensuring sufficient organs at risk protection for treatment plans 
that would not have been acceptable with 3D-CRT.  
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Purpose/Objective: Cancer epidemiology has been extensively 
studied in developed countries. However, data addressing the 
epidemiology and the impact of the implementation of screening 
programs for breast cancer in the Middle East are scarce. We present 
a detailed epidemiological analysis of breast cancer in the Jordan 
national cancer registry with special focus on presenting the impact of 
the implementation of a nationwide screening program for breast 
cancer in 2006 in an attempt to aid the continuously evolving 
strategies for improved cancer surveillance and control. 
Materials and Methods: Data from the Jordan national cancer registry 
addressing the periods from January 1996 to December 2008 were 
meticulously reviewed. The Jordan national cancer registry which was 
established in 1996 utilizes a passive and active capture system via 
liaison personnel throughout the country.Tumor stage was classified 
into local, regional, distant or unknown. Crude incidence rates are 
expressed per 100,000 population. 
Results: Between 1996 and 2008; a total of 7,794 breast cancer cases 
were registered. Overall, 7,018 patients (89.8%) harbored ductal 
carcinoma while 478 patients (6.1%) harbored lobular carcinoma. The 
crude incidence rate of breast cancer was 20 in 1996, 21.5 in 1997, 
20.2 in 1998, 22.9 in 1999, 23.7 in2000, 23.9 in 2001, 20.5 in 2002, 
22.1 in 2003, 24.9 in 2004, 25.5 in 2005,27.5 in 2006, 29.3 in 2007 and 
29.9 in 2008. Concerning the age distribution of breast cancer cases; 
28.8% occurred in 40-49, 26.4% in 50-59, 18% in 60-69,16.6% in 30-39 
and 6.8% in 70-79 age groups. The median age was 51 years(range, 16-
100 years). Overall for breast cancer; 1,412 patients (17.4%)harbored 
local disease, 1,504 patients (19.3%) harbored regional disease, 
and1,572 patients (18.3%) harbored metastatic disease while in 3,306 
patients (45.2%)staging data was missing. For patients with known 
cancer stage, 1,954 out of a total of 2,712 patients (72.1%) presenting 
prior to 2006 and 1,047 out of a total of 1,796 patients (58.3%) 
presenting after 2006 harbored loco-regional disease.  
Conclusions: This study represents the first comprehensive 
assessment of the epidemiology of breast cancer in Jordan basing a 
framework for enhancing strategic health plans regarding cancer 
surveillance and control in Jordan and the Middle East.  
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Purpose/Objective: With this study we intended to evaluate the dose 
received by axillary levels I and II, when irradiating the breast with 
